USFDA3 May 2025, 02:51 pm
Bharat Parenterals' Subsidiary, Innoxel Lifesciences, Successfully Clears US FDA Inspection
AI Summary
Bharat Parenterals Limited has announced that its subsidiary, Innoxel Lifesciences Pvt. Ltd., has successfully cleared the United States Food and Drug Administration (US FDA) inspection at its manufacturing facility in Vadodara, Gujarat. The inspection took place from April 28, 2025, to May 2, 2025, resulting in one minor observation under Form 483. This observation is procedural in nature. The company is committed to maintaining the highest quality standards and compliance at all times. The successful completion of this inspection strengthens the company's position in regulated markets and enhances its readiness to serve global customers with high-quality pharmaceutical products.
Key Highlights
- Bharat Parenterals Limited's subsidiary, Innoxel Lifesciences Pvt. Ltd., has successfully cleared the US FDA inspection.
- The inspection took place from April 28, 2025, to May 2, 2025, at the manufacturing facility in Vadodara, Gujarat.
- One minor observation was issued under Form 483, which is procedural in nature.
- The company is committed to maintaining the highest quality standards and compliance.
- The successful completion of the inspection strengthens the company's position in regulated markets and enhances its readiness to serve global customers.